Monthly Archives: October 2020
In an expansion cohort of a phase I CHRYSALIS study, the RP2CD (recommended phase 2 combination dose) of amivantamab antibody combined with 3rd generation EGFR TKI lazertinib to exam patients in osimertinib resistant(n=45) or treatment-naïve(n=20) EGFR-positive (exon 19 deletions and L858R) NSCLCs. In osimertinib resistant group, the objective response rate(ORR) was 36% with one patient complete response, response was seen irrespective of first or second lines used osimertinib.
ERBB2 exon 20 insertion accounts for 2-3% of the total mutations of non-small cell lung cancer. However, there is still an unmet need for treating patients with this kind of mutation. The phase 2 ZENITH20 trial is aimed to study the activity of poziotinib in NSCLC patients with either an EGFR exon 20 insertion or an ERBB2 exon 20 insertion.
Urothelial carcinoma (UC) is one of the malignant diseases with a poor five-year survival rate. Platinum-based regimen is the major treatment option for patients with UC. Recently, immune checkpoint inhibitors had been demonstrated anti-tumor activity in UC. Avelumab is an anti–PD-L1 antibody that has been approved with first-line maintenance treatment in UC followed the phase 3 JAVELIN Bladder 100 trial.
SAN FRANCISCO and TAIPEI, Taiwan, Oct. 22, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Sonny Hsiao, Ph.D., chief
executive officer, will present a corporate overview at the upcoming 7th Annual China Healthcare Summit on November 9, 2020.